Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
DSIP, delta sleep-inducing peptide, is a chain of nine amino acids found in the 1970s in the blood leaving a stimulated rabbit’s brain, and sold today as a nightly injection or nasal spray for sleep, stress and recovery. What has been tested in people for sleep is a handful of small sleep-laboratory studies from 1981 to 1992, all given into a vein; the two independent placebo-controlled ones found effects their authors called “not likely to be of major therapeutic benefit” and “of little clinical significance”. The FDA counts 209 people given 25-150 nmol/kg intravenously for 1 to 15 days; nasal dosing appears in a two-month eye study and a 2001 letter; and no study in people has used the route nearly every product uses: an injection under the skin.
This review sets out what has been tested in people, what comes only from animals, cells or reasoning, and where DSIP stands with the FDA. It is part of our peptide library; our providers prescribe some of the peptides reviewed here, and we earn from that care.
At a glance
- FDA status
- Not FDA-approved, and outside the FDA’s and HHS’s compounding policies.
- Evidence in people
- The FDA counts 209 people, into a vein, for 1 to 15 days; the controlled sleep studies ran 1981-1992.
- The claim you’ve heard
- Deep sleep from a nightly injection under the skin: never tested in people.
- Doses tested in people
- 25-150 nmol/kg into a vein, by the FDA’s count. No study has given it under the skin.
- Sport
- Not named on WADA’s 2026 or 2027 List; WADA says an unnamed peptide may still be prohibited.
What DSIP is
DSIP is a nonapeptide — nine amino acids in a row, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Monnier and Schoenenberger’s group in Basel isolated it in the 1970s from the blood of rabbits whose thalamus was being stimulated, and named it for the delta waves it raised. The FDA, which calls it emideltide, notes that the name “is a common name and not a USAN, INN, or IUPAC name.”
Two different substances are sold as “DSIP”: the free base and emideltide acetate, distinct bulk drug substances to the FDA, which dissolve differently. “None of the websites searched indicate whether their marketed products contain the base or a salt or ester of emideltide.” Neither has a pharmacopoeia monograph to be tested against, and neither is a registered drug in any country the FDA searched.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: DSIP is not an FDA-approved medicine, and it is not on the FDA’s list of substances a pharmacy may use to compound one. Its own staff proposed in 2026 that it not be added, and it is not among the six peptides in HHS’s draft policy; HHS is the FDA’s parent department.
As of November 19, 2026, DSIP (emideltide) is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. The FDA’s staff proposed in 2026 that it “NOT be included” on that list, it is in none of the categories of the FDA’s interim compounding policies, and it is not one of the six peptides in HHS’s October 2026 interim policy. The FDA says it “has not identified safety-related information regarding emideltide for the proposed route of administration.”
The FDA’s own review
A withdrawn nomination is not a judgment on a substance, but it leaves emideltide in none of the FDA’s compounding categories, in a table of substances “nominated but withdrawn” under a column headed “Potential significant safety risks”. Its entry reads: “Compounded drugs containing emideltide may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified safety-related information regarding emideltide for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.” The last two sentences say it has no information, not that the peptide is safe.
What that means for a compounded prescription
The FDA’s guidance says: “A drug product compounded from a bulk drug substance that does not meet any of these three conditions is not eligible for the exemptions in section 503A and may violate the FD&C Act.” A 2020 warning letter listed DSIP among such substances; no letter naming it was found for this review, in a search that was not exhaustive.
The advisory committee
The FDA’s advisory committee discussed emideltide on July 24, 2026; the FDA has published no minutes, transcript or written vote count (its recording of the meeting is online), and news reports say it voted against adding it. Such a vote is advice in any case: these committees “make non-binding recommendations to the FDA.”
HHS’s draft policy
On October 30, 2026 HHS announced a draft interim policy; in announcing it, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy, federal facility or licensed physician compounding with certain peptide bulk drug substances. The policy document says HHS “does not intend to take action” against them “when all of the following circumstances are present”. Its Appendix A names six — “1. BPC-157 2. Epitalon 3. KPV 4. MOTS-c 5. Semax 6. TB-500” — and DSIP is not among them. None of those six is on the 503A list either; what the policy gives them is a stated intention not to enforce, and, HHS said, it “does not establish any rights for any person and is not binding on HHS or the public.” It is not approval: “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.” Whether the policy is operative today is not stated in either document.
Sport
DSIP is not named on WADA’s 2026 or 2027 Prohibited List, the 2027 one in force from 1 January, which is not clearance: S0 covers “Any pharmacological substance … with no current approval by any governmental regulatory health authority for human therapeutic use”, and WADA says that “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited.”
Claims you’ll see, and why sources disagree
Pages about DSIP contradict each other, and this page. Three things explain the spread.
- Animal findings reported as human findings. The delta-wave story is an animal story; the one human EEG study under anaesthesia, in 2009, found DSIP “paradoxically, significantly reduced delta rhythm”.
- Which studies get counted. The biggest sleep numbers come from studies with no placebo group, written by the peptide’s discoverers.
- Numbers with no study behind them. One ingredient encyclopedia says DSIP “May reduce nighttime awakenings by up to 40% in clinical trials”; no published trial reports it, and with no dose-finding study by the route people use, the figures online come from sellers and forums.
This cuts both ways: no study in people is not evidence that DSIP does nothing, nor that it is safe.
| Claim you’ll see | Level of evidence | Verdict |
|---|---|---|
| “Promotes deep, restful sleep by increasing delta wave activity” | Animal and lab studies; one measurement in people | Contested: the animal studies disagree, and the human EEG found delta reduced |
| “May reduce nighttime awakenings by up to 40% in clinical trials” | None found | Not supported: no published trial reports that figure |
| “Enhances stress resilience by lowering cortisol levels” | Tested in people | Contradicted: cortisol “unaffected” in one study, “almost identical” to placebo in another |
| “Normalizes sleep architecture without sedation” | Reported in people | Partly supported, from studies without placebo |
| Combining DSIP with ipamorelin “for patients who also need GH optimization” | Tested in people, for DSIP alone | No growth-hormone effect in people; the combination is unstudied |
| Microgram doses under the skin or into the nose, on and off in cycles | None | No study set them; the sleep and withdrawal studies dosed into a vein |
| “Rapid relief of alcohol and opioid withdrawal symptoms” | Reported in people | Uncontrolled 1983-84 reports; the standard-scale study got 2 of 7 through |
| “Neuroprotective benefits”; marketing for cancer, Alzheimer’s and Parkinson’s | Animal and lab studies; nothing in people | Not tested in people; the stroke study’s infarct difference was not significant |
What the evidence consists of
No trial of DSIP is registered: a ClinicalTrials.gov search under its three names returned nothing on 18 November 2026. Every human study below is from 1981 to 2014, mostly into a vein.
Tested in people
These had a comparison group: placebo, saline or a controlled comparison.
| Study | People | Design | What happened | Funding or limits |
|---|---|---|---|---|
| Schneider-Helmert et al. 1981 (healthy); Schneider-Helmert & Schoenenberger 1981 (insomnia) | 6 and 6 | Randomised, double-blind placebo crossovers; one 9 am infusion; three nights at bedtime | Healthy: sleep “increased by 59% (median of total sleep time) within a 130-min interval”, with delayed effects 13-22 h later. Insomnia: an arousing first hour, then sleep-promoting effects to the sixth, no change in time to fall asleep, only “tendencies” toward fewer awakenings | A co-discoverer authored both; results “reported in p values”, no placebo numbers |
| Monti et al. 1987 | 6, severe chronic insomnia | Randomised, double-blind placebo crossover, two 9-night blocks | About 20 minutes more sleep, slightly shorter latency, but “no significant differences … compared to baseline or placebo”; quality unchanged; mild drowsiness | Authors: “of little clinical significance” |
| Bes et al. 1992 | 16, chronic insomnia | Double-blind placebo, parallel matched groups, 5 nights | Numerically shorter latency and higher sleep efficiency; “none of the other variables … showed any differences neither between nor within the groups” | Authors: “not likely to be of major therapeutic benefit”; the latency difference may be an artefact |
| Pomfrett et al. 2009 | 24 surgical patients (12 DSIP, 12 saline) | Randomised, saline-controlled, under isoflurane | “significantly increased heart rate, decreased HRV and, paradoxically, significantly reduced delta rhythm” | Commercial supplier; anaesthetised patients |
| Four hormone studies, 1989-1995 | 54 healthy adults | Placebo- or saline-controlled single infusions | ACTH fell in two; cortisol “unaffected” in one, “almost identical” to placebo in another; growth hormone, prolactin, vasopressin unchanged | Surrogate endpoints; no sleep measured |
| Kresiun & Godlevskii 2014; Kresyun 2014 | 30 with diabetes, 15 healthy | Controlled; into the nose, two months | Visual evoked potentials recovered faster after photostress, 137.2 ± 11.3 → 95.1 ± 6.8 s | Single centre; abstract only |
Four measured sleep; a fifth recorded an EEG under anaesthesia. The two studies run independently of the discoverers found effects their authors called of little clinical significance and unlikely to be of major benefit; the clearest positive result is a 59% rise in median daytime sleep in six healthy volunteers dosed in the morning; and the EEG under anaesthesia found less delta, not more. None published a between-group difference with a confidence interval, so the size of any effect — and whether the data are equally compatible with none — cannot be read from them. The FDA finds “insufficient evidence concerning effectiveness” intravenously and none at all by the subcutaneous route.
Reported in people
These had no placebo group: they cannot separate the peptide from the setting or from time.
| Study | People | What was given | What was reported | Limits |
|---|---|---|---|---|
| Schneider-Helmert 1986 and 1987 | 18 and 14, chronic insomnia (1986: 9 aged 29-59, 9 aged 60-83) | Each evening, six nights and seven | 1987: latency 58.4 → 38.9 → 27.6 min, time awake 120.8 → 78 → 65.6 min, total sleep 313 → 363.1 → 385 min. 1986: all four measures improved, the older group gaining 97 minutes against 57 | No placebo arm in either, despite 1987’s label; outside controls |
| Schneider-Helmert & Schoenenberger 1983 | Five small series, healthy and insomnia | Different infusion speeds | Effect from the second hour, “duration of up to 20 h”; the same dose was “completely ineffective if infused over 1 minute” | FDA: “insufficient details on study design” |
| Kaeser 1984 | 7, severe insomnia | 10 injections within 14 days | Sleep normalised in all but one patient, over 3-7 months of follow-up | Open; adverse events not addressed |
| Dick et al. 1983 and 1984 | 67 and 107 patients in opiate or alcohol withdrawal | 1984: up to six doses a day, up to six days | 1983: “a beneficial effect in 48” of the 49 assessable. 1984: of 60 opioid patients, 40 assessed showed “good decrease or complete disappearance” of objective withdrawal signs | Open; three serious events in 1984 (see safety); many relapsed into insomnia |
| Backmund et al. 1998 | 7, opioid dependence | Fixed schedule over 7 days | Withdrawal score 34.4 → 17.8 after the first injection; only 2 of 7 completed | Authors: “an open question whether DSIP could be an effective alternative detoxification approach” |
| Larbig et al. 1984; Odin et al. 2004 | 7 with chronic pain; 11 elderly with diabetes | Open pilots; the 2004 one gave Deltaran, a mixture | Pain fell significantly in 6 of 7; better quality-of-life and sleep scores; glucose and growth hormone fell | Abstracts only; doses not stated |
Three single patients and a letter are also reported: a man with 10 years of narcolepsy whose sleep attacks fell from six to three over 12 doses — the whole human record for narcolepsy; one whose delayed sleep phase advanced “by 5 hours”; one whose insomnia after a brain-stem haemorrhage improved “both quantitatively and qualitatively”; and a 2001 letter on nasal DSIP and a brain-wave response, its details unverified.
Animal studies
- The delta-wave finding, and its contradictions. DSIP raised EEG delta power in rabbits (into the brain, with more spindle activity; into a vein, “within 5 h”) and in rats (“between 1 and 4.5 h”, dose dependently), and prolonged non-REM sleep in cats. Another group “failed to detect increases in the power of EEG delta waves” in rats at all: “The reasons underlying the discrepant findings have not been discussed or elucidated.”
- The opioid system. Naloxone, an opioid blocker, “prevented the ability of an emideltide-related BDS … to prolong sleep duration” in rats, and its pain relief in mice and rats. The FDA draws a risk from the same mechanism: endorphin release in reward regions “could have reinforcing properties that could … contribute to the development of addiction”, with no study of abuse potential.
- The longevity claim comes from one study of Deltaran, a DSIP-and-glycine mixture, in female mice dosed five days a month for life: their last 10% survived “approximately 20% longer” and tumour rates fell. But glycine itself “has anti-tumorigenic properties”, and the study “is not adequately designed to assess the potential … to induce carcinogenicity”.
- Never done in animals either: no repeat-dose, developmental or reproductive toxicity studies, no two-year carcinogenicity study, no abuse-liability study, no subcutaneous pharmacokinetics.
Lab studies and how it is thought to work
The FDA’s statement on mechanism runs against the marketing: “An elevation of endogenous emideltide concentration has been shown to be associated with suppression of both slow-wave sleep (SWS) and REM sleep.” In people, plasma DSIP-like immunoreactivity is lower in REM and slow-wave sleep than when awake and falls “at the transition from wakefulness to sleep”: the body’s own DSIP-like material does not rise with deep sleep.
In cells, DSIP does not bind opioid receptors, but it “has been reported to facilitate the release of enkephalins from neurons”, the body’s own opioid-like molecules — the leading explanation for the animal findings and the basis of the FDA’s addiction concern. Beyond that the molecule has no established biology: no gene, precursor protein or receptor has ever been identified, and a literature search from 2015 to 2026 found nothing newer. The standard review of the field is blunt: “the hypothesis regarding DSIP as a sleep factor is extremely poorly documented and still weak.”
An almost entirely positive record from mostly one group, with no dose-finding study in it, is itself a reason for caution — and it was built mostly on infusions into a vein, mostly in people with diagnosed insomnia, withdrawal or narcolepsy.
Dosing: what has been tested and what is reasoned
What the studies gave. This is the published record, not a schedule. All the sleep studies in the tables above dosed into a vein by weight: 25 nmol/kg (about 21 mcg/kg) in most, 30 nmol/kg in two (18 people in 1986, 14 in 1987), infused over four minutes in three, on one to seven days, or ten injections within a fortnight in one. In withdrawal, 107 patients had 25 nmol/kg up to six times a day for up to six days and seven had 35 nmol/kg on a seven-day schedule; the anaesthesia trial gave boluses of 25-100 nmol/kg; and the highest doses, 30 nmol/kg in week one, 150 then 90 in week two, 70 in week three, are in one case report. The FDA’s count of intravenous use is “doses of emideltide between 25 – 150 nmol/kg have been administered intravenously to 209 subjects for 1 to 15 days”.
The routes people ask about. No published study in people has given DSIP under the skin or under the tongue: “There are no safety data for emideltide (free base) and emideltide acetate administered by the nominator proposed SC ROA.” The only nasal dosing found with a stated dose measured an eye response.
What circulates online. The figures sold with DSIP match no sleep study: an ingredient encyclopedia, a review site and a physician-branded page all put the amount in the tens to hundreds of micrograms a day, under the skin or into the nose, with cycles on and off. No study set any of them, and the doses the sleep studies did give work out several times larger. One of those pages calls its own figures “Anecdotal” and “not a prescribing guide”.
The pharmacology, point by point.
- Measured: a half-life of 5-10 minutes in human serum, 2-6 minutes in animals, reaching cerebrospinal fluid 30 minutes after an intravenous dose in dogs. On human intestinal cells DSIP was “rapidly metabolized” and none crossed intact, so oral and sublingual products have no pharmacological basis. (The FDA’s “short plasma half-life of 8 minutes” carries no citation in its own document.)
- Inferred: a half-life of minutes cannot cover a night through blood levels, yet effects are described from the second hour and lasting 6 to 20 hours. If DSIP does anything it is through something downstream — what, no study has established — so blood levels are not what a dose would be chasing.
- Inferred: infusion speed changed the result in the one study that varied it, so intravenous findings say little about an injection under the skin. “In general, SC ROA is associated with increased immunogenicity compared to IV ROA”: today’s route is the higher-risk side of that comparison, without the effectiveness data.
- Inferred: no human study measured anything that predicts benefit, so nothing can be followed to tell whether a dose is working, and no study has tested whether monitoring helps.
What nobody knows. There is no human data for the route nearly all products use, no dose-finding study by any route, and nothing beyond 15 days in the FDA’s count. A dose is a prescriber’s decision for one patient.
Safety, and who should be most cautious
In the sleep studies, intravenous DSIP “was found to be well tolerated and not associated with significant AEs”. The events recorded were “Warmth, heaviness, dry mouth, deep respiration and headache (1 case of prolonged headache)” in healthy volunteers, headache, and mild drowsiness.
The withdrawal studies produced the only serious events. Among 107 patients in opiate or alcohol withdrawal, “no significant AEs were reported in 95 of the 107 subjects”; nine had “minor transient side effects such as perspiration, headaches, nausea, and vertigo”; and three had serious events — “two subjects experienced hypotension at the beginning of the first injection and the third subject experienced repetitive episodes of general discomfort with perspiration and nausea lasting 15 minutes”. One of those three had a second injection and “progressive hypotension”. Withdrawal itself causes many of the same symptoms, and the authors blamed some events on “solubility difficulties” with certain vials. Patients who improved also relapsed into “anxiety with marked insomnia within 24-72 hours after treatment discontinuation”, only 13 escaping the insomnia. The one modern controlled study found a cardiovascular signal: faster heart rate, lower heart-rate variability, lighter anaesthesia.
There are no post-marketing reports: the FDA’s Adverse Event Reporting System “retrieved zero reports” through 3 March 2024. That is not evidence of safety: it searched the name emideltide, and what people buy is sold as research chemicals, outside any dispensing record.
The FDA’s own conclusions: emideltide “is considered not well-characterized from the physical and chemical characterization perspectives”; “we cannot rule out the potential for immunogenicity associated with these impurities and peptide related aggregates”; and “stimulation of the opioid system by emideltide could lead to development of addiction”, with no study to inform that liability.
Most reason for caution lies with those for whom a fall in blood pressure, a faster heart or a nudge to the opioid system would matter most.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy or breastfeeding | No data at all, and no animal reproductive studies | FDA’s review |
| Under 18 | No study in children; the youngest participant found was 17 | The 1993 study in women aged 17-36 |
| A history of cancer | Only the mouse study of a DSIP-and-glycine mixture, which may show a glycine effect | Animal studies |
| Opioids, alcohol, benzodiazepines, other sedatives | Never studied together in people; an opioid blocker blocked the animal sleep and pain effects | Animal studies; theory |
| ACE inhibitors such as captopril | They target an enzyme that breaks DSIP down, so breakdown could slow | Lab studies; theory |
| Low blood pressure, or heart disease | Two withdrawal patients had hypotension at the first injection; heart rate rose and variability fell under anaesthesia | Reported and tested in people |
| A history of addiction | Endorphin release “could have reinforcing properties”; no abuse-liability study exists | Animal studies; theory |
| Tested athletes | Not named on WADA’s Lists, which is not the same as permitted | WADA’s Lists |
Nobody with liver or kidney disease, nobody with cancer and no healthy adult who sleeps badly has been studied: the participants were adults with chronic insomnia aged 29 to 83, adults in withdrawal, healthy volunteers, one narcolepsy patient and two diabetic groups.
Product quality
No independent published analysis of DSIP products sold online exists, so there is no failure rate to quote in either direction. One seller posts its own per-lot purity, sterility and endotoxin certificates — a vendor’s documents for its own lots.
The FDA’s market survey is the better picture. It found US clinics, medical spas, concierge services and online retailers “marketing emideltide-related drug products for various uses including sleep disorders, stress reduction, pain management, cancer, neurodegenerative diseases … alcohol and drug detoxification”, and “Many of the websites do not describe or clearly state whether the emideltide-related products marketed are compounded.” No compounding pharmacy was found marketing it, and no outsourcing facility has reported compounding it.
“Research use only” is a label, not a grade of medicine. The FDA’s warning letters to peptide sellers say: “Despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ … evidence obtained from your websites establish that your products are intended to be drugs for human use” — and there the products are “unapproved new drugs … in violation of sections 505(a) and 301(d)”.
The characterisation gap is the quality story. The certificates of analysis submitted with the nominations lacked impurity limits and had no endotoxin, bioburden or residual-solvent testing, and one gave a molecular formula that “does not correspond to any emideltide structure”. Because sellers do not say whether they sell the free base or the acetate, inconsistent naming “represent a safety risk for patients as they may be dosed with a different bulk drug substance than the physician ordered”.
What we make of it
This is our reading of the evidence above, for the physician who reviews these pages to confirm or rewrite: judgment, not a finding.
On the evidence, DSIP is unproven and experimental. What it is sold for — better sleep from a nightly injection under the skin — has no support in people by that route. The two independent controlled studies were weak or negative; the one human EEG study under anaesthesia went the wrong way; the body’s own DSIP-like material falls as people fall asleep; and no gene, precursor or receptor has been found.
Thin is not disproved, and we would be overstating it the other way if we said DSIP does nothing. The gap between a half-life of minutes and effects reported hours later points at something downstream, a signal that would justify a proper trial. Withdrawal is where the reports are most consistent — two uncontrolled series described improvement in 48 and 40 patients — but it is also where the only serious adverse events occurred.
What would change this: an independent placebo-controlled trial by the route people use, at a dose a dose-finding study set; a mechanism that makes the sleep claim coherent; and a published analysis of what is in the products on sale. Until then, the honest description is a peptide with an interesting fifty-year-old story, a contested biology and a market far ahead of its evidence. For whom, if anyone, it might make sense, after what, with what monitoring and when to stop are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
Peptide care here starts with lab testing and a visit. A provider decides whether any peptide suits a patient and, if so, which one; you don’t pick one from a menu, and for some people the answer is that no peptide is a good idea. How it works, and what it costs, is on our peptide therapy page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A registered trial, by any route, would change the picture more than anything else here; none is under way.
- A final rule naming emideltide, either way, would settle its status: HHS’s policy runs until “a peptide bulk drug substance is addressed in a final rule”, and the FDA “does not intend to take action against a compounder” when its interim policy’s conditions are met, also until a final rule.
- Minutes or a transcript of the July 2026 vote would replace the news reports this page relies on; HHS may also revisit its draft policy, replaced once already on 9 November 2026.
- Each year’s WADA List, which we re-read; and any published analysis of what is sold.
Common questions
Does DSIP help you sleep?
The studies are too small and too old to settle it, and the best are not encouraging: the two studies run independently of the peptide’s discoverers called the treatment “not likely to be of major therapeutic benefit” and any improvement “of little clinical significance”. The larger positive studies had no placebo group, and none used the form and route sold today.
Can a doctor prescribe DSIP?
Nothing we read answers that: the sources address compounding, not prescribing. DSIP is not FDA-approved, so anything dispensed is a compounded medicine made on a prescription for one patient, and the FDA says such a drug “is not eligible for the exemptions in section 503A and may violate the FD&C Act”.
Is DSIP safe?
Nobody can answer that from the evidence that exists. Short intravenous courses were called well tolerated; in withdrawal, three of 107 patients had serious events, two of them hypotension at the first injection. The FDA calls the substance “not well-characterized” and notes that nobody has studied the addiction risk its mechanism implies.
How often was it given in the studies?
Dosing in the sleep studies was intravenous and short: on one to seven days, mostly in the evening, or ten times over a fortnight; in withdrawal, up to six times a day for up to seven days. The FDA counts intravenous use of 1 to 15 days; an eye study dosed into the nose for two months; none was under the skin.
Is DSIP banned in sport?
It is not named on WADA’s 2026 or 2027 List, which is not the same as permitted. S0 covers any substance with “no current approval by any governmental regulatory health authority for human therapeutic use”, and WADA says an unnamed peptide “may still be prohibited”.
Sources
Show all 48 sourcesHide sources
- FDA Briefing Document: Emideltide-Related Bulk Drug Substances (Emideltide (free base) and Emideltide acetate), Pharmacy Compounding Advisory Committee, July 23-24, 2026. US Food and Drug Administration, 2026.
- Pharmacy Compounding Advisory Committee Meeting July 24, 2026 — FDA Presentations. US Food and Drug Administration, 2026.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. US Food and Drug Administration, 2026.
- Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. US Food and Drug Administration, 2026.
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
- Warning letter: Tailor Made Compounding LLC, MARCS-CMS 594743. US Food and Drug Administration, 2020.
- Warning letter: Summit Research Peptides (12/10/2024). US Food and Drug Administration, 2024.
- Warning letter: Gram Peptides (03/31/2026). US Food and Drug Administration, 2026.
- Warning letter: Peak Performance Peptides (08/24/2026). US Food and Drug Administration, 2026.
- Prohibited List. World Anti-Doping Agency, 2026 and 2027 Lists.
- ClinicalTrials.gov search: “delta sleep-inducing peptide” OR DSIP OR emideltide. US National Library of Medicine, 2026.
- Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol, 1981.
- The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 1981.
- Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology, 1983.
- Effects of DSIP on narcolepsy. Eur Neurol, 1984.
- Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol, 1986.
- Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol, 1987.
- The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia. Dtsch Med Wochenschr, 1987.
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology, 1992.
- Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res, 1987.
- A clinical trial with DSIP. Eur Neurol, 1984.
- Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. Eur Neurol, 1984.
- Sleep disturbances in a case of brain-stem lesions; pharmacological study. Electroencephalogr Clin Neurophysiol, 1984.
- Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology, 1983.
- DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol, 1984.
- Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol, 1998.
- Intranasal administration of delta sleep-inducing peptide increases P300. J Clin Psychopharmacol, 2001.
- Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol, 2009.
- Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology, 1989.
- Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion. Psychoneuroendocrinology, 1995.
- Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Horm Res, 1994.
- Delta sleep-inducing peptide administration does not influence growth hormone and prolactin secretion in normal women. Psychoneuroendocrinology, 1993.
- Using deltalicin for the treatment of patients with diabetic retinopathy. Eksp Klin Farmakol, 2014.
- The influence of deltalycyn and transcranial cerebellar stimulation upon recovery of retina after photo stress in patients with diabetic retinopathy. Rev Med Chir Soc Med Nat Iasi, 2014.
- Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide. Adv Gerontol, 2004.
- Delta-sleep-inducing peptide (DSIP): an update. Peptides, 1986.
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem, 2006.
- JmjC-domain-containing histone demethylases of the JMJD1B type as putative precursors of endogenous DSIP. Peptides, 2011.
- hDIP — a potential transcriptional regulator related to murine TSC-22 and Drosophila shortsighted (shs) — is expressed in a large number of human tissues. Biochim Biophys Acta, 1996.
- Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep. J Clin Endocrinol Metab, 1994.
- Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides, 1995.
- Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy. Peptides, 1995.
- Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides, 1987.
- Transport and metabolism of delta sleep-inducing peptide in cultured human intestinal epithelial cell monolayers. Drug Metab Dispos, 1995.
- Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev, 2003.
- Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules, 2021.
